InsiderTrades

Form 4 for BBIO BridgeBio Pharma, Inc.

Accepted 2025-02-27 00:00:00 ET · period of report 2025-02-25 · accession 0000950170-25-029262 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2025-02-27 2025-02-25 BBIO STEPHENSON BRIAN C CFO, Treas S - Sale+OE $33.19 -8,500 102.5K -8% -$282.1K
DT 2025-02-27 2025-02-25 BBIO STEPHENSON BRIAN C CFO, Treas M - OptEx $17.00 +8,500 111.0K +8% +$144.5K
DT 2025-02-27 2025-02-25 BBIO STEPHENSON BRIAN C CFO, Treas M - OptEx $0.00 -8,500 440.2K -2% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-02-25 S D 8,400 $33.18 102,564 D — — (F2) Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
2 Common Common Stock 2025-02-25 S D 100 $34.18 102,464 D — —
3 Common Common Stock 2025-02-25 M A 8,500 $17.00 110,964 D — —
4 Derivative Stock Option (right to buy) 2025-02-25 M D 8,500 $0.00 440,170 D $17.00 · — to 2029-06-26 8,500 Common Stock (F3) The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.